Abcam, ab250793, Anti-CES2 antibody [EPR14856] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal EST2 antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14856,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250793 is the carrier-free version of
ab184957
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Carboxylesterase 2 (CES2) also known as intestinal carboxylesterase is an enzyme with a molecular mass of approximately 60 kDa. CES2 hydrolyzes esters and amides affecting metabolism of drugs and xenobiotics. It is found mainly in the liver and small intestine with lesser expression in the colon kidney and brain. This distribution enables CES2 to play a role in both intestinal and systemic drug metabolism.
Biological function summary
CES2 acts in the hydrolysis process converting prodrugs into active compounds. It functions independently and is not typically part of a larger complex. This enzyme demonstrates broad substrate specificity impacting the metabolic activation of several therapeutic agents. Its activity affects the bioavailability and activation of medicines such as irinotecan and capecitabine which are used in cancer treatments.
Pathways
CES2 takes part in the drug metabolism pathway involving cytochrome P450 enzymes. It interacts with CYP3A4 one of the key enzymes in this system and facilitates the conversion of chemical compounds into pharmacologically active or inactive metabolites. CES2 also participates in lipid metabolism affecting the ester and triglyceride hydrolysis alongside lipases and other related enzymes.
CES2 has implications in colorectal cancer and liver disease conditions where altered drug metabolism influences disease progression and treatment efficacy. It shows associations with irinotecan activation a drug used for treating colorectal cancer and links with UDP-glucuronosyltransferases (UGTs) that also engage in drug metabolism. Understanding CES2's function aids in predicting patient responses to drug therapies and refining treatment strategies for these conditions.